...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >MONITORING OF EFFECTIVENESS OF SPIRONOLACTONE THERAPY AND ITS COMBINATIONS WITH FUROSEMIDE TO LIVER CIRRHOSIS AND ASCITES IN RSUP H. ADAM MALIK MEDAN
【24h】

MONITORING OF EFFECTIVENESS OF SPIRONOLACTONE THERAPY AND ITS COMBINATIONS WITH FUROSEMIDE TO LIVER CIRRHOSIS AND ASCITES IN RSUP H. ADAM MALIK MEDAN

机译:螺内酯治疗及其与呋塞米联用对RSUP H. ADAM MALIK MEDAN肝硬化和腹水影响的监测

获取原文

摘要

Objectives: Spironolactone and furosemide are diuretics used to treat liver cirrhosis with ascites, but not case studies have been found to distinguish the effects of spironolactone and its combination with furosemide in cases of cirrhosis accompanied by ascites. This study aims to determine the effectiveness of spironolactone therapy and its combination with furosemide to liver cirrhosis patients accompanied ascites. Methods: This research was done by cross-sectional prospective method. 26 patients in RSUP H Adam Malik Medan for 3 months were divided into two groups. The first group of nine patients, age between 39 and 65 years, was given spironolactone. The second group of 17 patients, age between 20 and 81 years, was given spironolactone combined with furosemide. The sample data were analyzed with statistics using Mann–Whitney U-test, SPSS program version 22. Result: Based on Mann–Whitney U statistic test, the value of Asymp. significance (2-tailed) 0.435 for urine Na/K at time, and Asymp. significance value (2-tailed) 0.628 24 h urine sodium examination, based on the value, it was concluded that there was no significant difference between spironolactone with its combination with furosemide. Even though the significant value were 0.628 mEq and 0.435 mEq (p>0.05). Conclusion: This study showed that the combination of spironolactone with furosemide was better than compared to spironolactone. Although there was not statistically significant difference if seen from the comparison of 24 h of urine sodium value with a normal value of 78 mEq.
机译:目的:螺内酯和速尿是用于治疗腹水型肝硬化的利尿剂,但尚未发现区分螺内酯及其与速尿联用对肝硬化并发腹水的疗效的案例研究。本研究旨在确定螺内酯治疗及其与速尿联合使用对伴有腹水的肝硬化患者的有效性。方法:本研究采用横断面前瞻性方法进行。 RSUP H Adam Malik Medan的26例患者,共3个月,分为两组。第一组9名年龄在39至65岁之间的患者接受了螺内酯治疗。第二组17例年龄在20至81岁之间的患者接受了螺内酯联合速尿。使用Mann–Whitney U检验,SPSS程序版本22,对样本数据进行统计分析。结果:基于Mann–Whitney U统计检验,Asymp的值。尿Na / K和Asymp的显着性(2尾)为0.435。显着性值(2尾)0.628 24 h尿钠检查,基于该值,得出的结论是螺内酯与呋塞米联合使用之间无显着差异。即使显着值为0.628 mEq和0.435 mEq(p> 0.05)。结论:这项研究表明,螺内酯与速尿联合使用的效果优于螺内酯。尽管从24小时尿钠值与正常值78 mEq的比较来看,差异无统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号